Search

Displaying results 4571 - 4580 of 8967 in total
  1. Drug

    AT-7519

    go.drugbank.com/drugs/DB08142
    Investigational

    AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

  2. Drug

    Tertomotide

    go.drugbank.com/drugs/DB12747
    Investigational

    Tertomotide is under investigation in clinical trial NCT01223209 (A Study, Combination, Immunologic Study of LTX-315 as adjunct to tertomotide in Patients Following Curative Surgery for Carcinoma). … It is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.

  3. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    first approved treatment for the disease whose labeling includes data from both. … [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]

  4. Drug

    Medrysone

    go.drugbank.com/drugs/DB00253
    Approved

    Medrysone is a corticosteroid used in ophthalmology.

  5. Drug

    Figopitant

    go.drugbank.com/drugs/DB12122
    Investigational

    Figopitant is under investigation in clinical trial NCT02209714 (Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers).

  6. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

  7. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    In addition, the vaccine contains a proprietary peptide UBITh®1a for enhanced immunogenicity, five identified peptides with Th or CTL epitopes to improve peptide solubility, and aluminum phosphate adjuvant … In rats, toxicity studies have so far shown favourable safety for this vaccine[L30653, L30658], Phase 1 trial is currently ongoing in Taiwan (NCT04545749).

  8. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. … Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.

  9. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.